Last reviewed · How we verify
Tamsulosine LP
Tamsulosine LP, marketed by Pierre Fabre Medicament, is an established treatment in the urology segment. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. However, the lack of disclosed primary trial results and revenue figures poses a significant risk in assessing its competitive landscape and market performance.
At a glance
| Generic name | Tamsulosine LP |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PERmixon® in LUTS Evaluation Study (PERLES) (PHASE4)
- Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamsulosine LP CI brief — competitive landscape report
- Tamsulosine LP updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI